Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1Phase 1/2 1

Status

Recruiting 23Not yet recruiting 15Completed 14Unknown 10Active not recruiting 5Terminated 2Withdrawn 1

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Pancreatic Neoplasms 3Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 195Nivolumab 146Carboplatin 134Specimen Handling 130Magnetic Resonance Spectroscopy 115Cyclophosphamide 109Paclitaxel 106Cisplatin 98Biopsy 97Radiotherapy 90durvalumab 81Dexamethasone 79atezolizumab 73Ipilimumab 62Gemcitabine 62Rituximab 59Doxorubicin 59Lenalidomide 55Docetaxel 55olaparib 52Bevacizumab 51Capecitabine 50Fluorouracil 49Etoposide 49Radiation 47Oxaliplatin 47Radiosurgery 42Prednisone 42venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × irinotecan sucrosofate × Clear all
NCT04233866 2026-05-05

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
176 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03764553 2026-04-07

LyRICX

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 2 Active not recruiting
320 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT04005339 2026-01-26

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Georgetown University

Phase 2 Active not recruiting
48 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gastrointestinal Neoplasms

NCT04390399 2025-12-15

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

ImmunityBio, Inc.

Phase 2 Active not recruiting
328 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06766019 2025-01-09

Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Active not recruiting
47 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡